Following a negative Allergan report by Favus Research, Evercore ISI analyst Umer Raffat said there are seven important points regarding Allregan to consider. He said analysts are not modeling 30%+ growth for Restasis; Kybella is not being modeled as a $1B drug; Viberzi is not a slow launch thus far; oral CGRP will not compete in a crowded market; Allergan's new antipsychotic, Vraylar, has a black box warning but that doesn't mean it's not good; its not true that the Teva/Allergan generics deal closing can't be done; and expense estimates may be a touch low, but not too low. The firm keeps a Buy rating and $400 price target on Allergan shares.